Lynch Asset Management’s Novo Nordisk NVO Stock Holding History

Lynch Asset Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.19M	Buy	108,350 +300	+0.3%	+$12.9K	1.42%	18
2026 Q1	$3.97M	Sell	108,050 -300	-0.3%	-$14.2K	1.33%	24
2025 Q4	$5.51M	Sell	108,350 -350	-0.3%	-$17.9K	1.73%	14
2025 Q3	$6.03M	Hold	108,700	–	–	1.93%	12
2025 Q2	$7.5M	Buy	108,700 +600	+0.6%	+$40.8K	2.65%	11
2025 Q1	$7.51M	Buy	108,100 +1,150	+1%	+$95K	3.37%	7
2024 Q4	$9.2M	Buy	106,950 +650	+0.6%	+$70.3K	3.73%	5
2024 Q3	$12.7M	Buy	106,300 +1,500	+1%	+$200K	5.32%	2
2024 Q2	$15M	Sell	104,800 -2,000	-2%	-$265K	6.39%	2
2024 Q1	$13.7M	Hold	106,800	–	–	6.45%	2
2023 Q4	$11M	Hold	106,800	–	–	6.33%	2
2023 Q3	$9.71M	Hold	106,800	–	–	6.38%	2
2023 Q2	$8.64M	Hold	106,800	–	–	5.56%	2
2023 Q1	$8.5M	Hold	106,800	–	–	6.1%	2
2022 Q4	$7.23M	Hold	106,800	–	–	6.22%	3
2022 Q3	$5.32M	Hold	106,800	–	–	4.77%	6
2022 Q2	$5.95M	Hold	106,800	–	–	4.87%	6
2022 Q1	$5.93M	Hold	106,800	–	–	4.24%	7
2021 Q4	$5.98M	Buy	+106,800	New	+$5.79M	4.15%	7

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Lynch Asset Management's NVO Position: Q2 2026 in Review

Lynch Asset Management increased its Novo Nordisk (NVO) stake by 0.28% in Q2 2026, buying an estimated $12.9K and bringing the position to 108,350 shares worth $5.19M. The position accounts for 1.42% of the portfolio, ranked #18.

Lynch Asset Management first reported a position in NVO in Q4 2021 and has held it in 19 quarters since. The position peaked at $15M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Lynch Asset Management held 108,350 shares of Novo Nordisk worth $5.19M as of Q2 2026.
Lynch Asset Management bought 300 Novo Nordisk shares in Q2 2026, an estimated $12.9K.
Novo Nordisk made up 1.42% of Lynch Asset Management's portfolio in Q2 2026, its #18 holding.
Lynch Asset Management first reported a position in Novo Nordisk in Q4 2021 and has held it in 19 quarters since.
Lynch Asset Management's Novo Nordisk position peaked at $15M in Q2 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Lynch Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.